Bausch + Lomb Corporation, an eye health company responsible for producing popular contact lens brands like Biotrue and Soflens, has gone public with an IPO. Shares were priced at $18, below the expected range. and rose slightly to around $19 in their first morning of trading on May 6.
Only you can make the decision on the time to leap... but here's some supporting information and analysis.
Historical closes compared with the last close of $13.6
| 1 week (2024-04-25) | -8.05% |
|---|---|
| 1 month (2024-04-04) | -17.33% |
| 3 months (2024-02-04) | -0.58% |
| 6 months (2023-11-02) | -20.65% |
| 1 year (2023-05-04) | -22.29% |
| 2 years (2022-05-04) | -24.44% |
| 3 years (2021-04-28) | N/A |
The gauge below shows real-time ratings that are based on 26 popular indicators such as moving averages, for specific time periods. It's not a recommendation but is simply technical analysis that can form part of your research.
Finder might not agree with the analysis and we take no responsibility. We also give no representations or warranty on the accuracy or completeness of the information provided on this page.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value. Check out the Bausch + Lomb Corporation P/E ratio, PEG ratio and EBITDA
Bausch + Lomb Corporation's current stock price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 34x. In other words, Bausch + Lomb Corporation stocks trade at around 34x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the United States stock markets on average as of November 09, 2023 (20.44). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
However, Bausch + Lomb Corporation's P/E ratio is best considered in relation to those of others within the industry or those of similar companies.
Bausch + Lomb Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $720 million.
The EBITDA is a measure of a Bausch + Lomb Corporation's overall financial performance and is widely used to measure a its profitability.
To put that into context you can compare it against similar companies.
Find out everything you need to know about technical analysis to help you become a better trader.
Technical analysis tells you a lot on a stock’s performance and can be a useful tool for your investing strategy, but isn’t a ready-made recipe for success.
A deep dive into the highlights and limitations of Frec.
A step-by-step guide on how to choose a financial advisor.
Explore the best bonuses for opening a new brokerage account.
First impressions of financial planning platform Domain Money and how it compares to the competition.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
Our star ratings for online brokerages are based on how they stack up in nine key categories.
The ins and outs of bundling stocks with this accessible investing option.